Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Bumetanide has been reported to alter synaptic excitation–inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models. However, clinical evidence of its efficacy in young patients with ASD is limited. This was investigated in the present clinical trial of 83 patients, randomised to the bumetanide group (bumetanide treatment, 0.5 mg twice daily) or the control group (no bumetanide treatment). Primary [Children Autism Rating Scale (CARS)], secondary [Clinical Global Impressions (CGI)], and exploratory [inhibitory (γ-aminobutyric acid, GABA) and excitatory (glutamate, Glx) neurotransmitter concentrations measured in the insular cortex (IC) and visual cortex (VC) by magnetic resonance spectroscopy (MRS)] outcome measures were evaluated at baseline and at the 3-month follow-up. Side effects were monitored throughout the treatment course. Compared with the control group, the bumetanide group showed significant reduction in symptom severity, as indicated by both total CARS score and number of items assigned a score ≥ 3. The improvement in clinical symptoms was confirmed by CGI. GABA/Glx ratio in both the IC and VC decreased more rapidly over the 3-month period in the bumetanide group than that in the control group. This decrease in the IC was associated with the symptom improvement in the bumetanide group. Our study confirmed the clinical efficacy of bumetanide on alleviating the core symptoms of ASD in young children and it is the first demonstration that the improvement is associated with reduction in GABA/Glx ratios. This study suggests that the GABA/Glx ratio measured by MRS may provide a neuroimaging biomarker for assessing treatment efficacy for bumetanide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31129-2 · Cited by 2,819
Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)
Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02408436 · Cited by 2,432
Critical period plasticity in local cortical circuits
Hensch, T. K. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1787 · Cited by 2,323
The K+/Cl− co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation
Rivera, C., Voipio, J., Payne, J. A., Ruusuvuori, E., Lahtinen, H., Lamsa, K., Pirvola, U., Saarma, M., & Kaila, K. (1999) · Nature · doi:10.1038/16697 · Cited by 2,152
Salience processing and insular cortical function and dysfunction
Uddin, L. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3857 · Cited by 2,083
Tomchek, S. D., & Dunn, W. (2007) · American Journal of Occupational Therapy · doi:10.5014/ajot.61.2.190 · Cited by 1,534
Robertson, C. E., & Baron-Cohen, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.112 · Cited by 1,157
Erroneous analyses of interactions in neuroscience: A problem of significance
Nieuwenhuis, S., Forstmann, B. U., & Wagenmakers, E.-J. (2011) · Nature Neuroscience · doi:10.1038/nn.2886 · Cited by 864
Oxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring
Tyzio, R., Nardou, R., Ferrari, D. C., Tsintsadze, T., Shahrokhi, A., Eftekhari, S., Khalilov, I., Tsintsadze, V., Brouchoud, C., Chazal, G., et al. (2014) · Science · doi:10.1126/science.1247190 · Cited by 601
Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders
Fiorentino, M., Sapone, A., Senger, S., Camhi, S. S., Kadzielski, S. M., Buie, T. M., Kelly, D. L., Cascella, N., & Fasano, A. (2016) · Molecular Autism · doi:10.1186/s13229-016-0110-z · Cited by 494
Cited by
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L.-S., Long, S., Ke, X.-Y., Fukunaga, K., Lu, Y.-M., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 258
Bennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
Juarez-Martinez, E. L., Sprengers, J. J., Cristian, G., Oranje, B., van Andel, D. M., Avramiea, A.-E., Simpraga, S., Houtman, S. J., Hardstone, R., Gerver, C., et al. (2023) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.08.009 · Cited by 48
Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?
Suprunowicz, M., Tomaszek, N., Urbaniak, A., Zackiewicz, K., Modzelewski, S., & Waszkiewicz, N. (2024) · Nutrients · doi:10.3390/nu16040549 · Cited by 44
“Disruptions in GABA activity in neurons are hypothesized to contribute to the pathogenesis of the disease [131].”
BackgroundBumetanide for autism: open-label trial in six children
Fernell, E., Gustafsson, P., & Gillberg, C. (2021) · Acta Paediatrica · doi:10.1111/apa.15723 · Cited by 34
Metadata
- Authors
- Zhang, L., Huang, C.-C., Dai, Y., Luo, Q., Ji, Y., Wang, K., Deng, S., Yu, J., Xu, M., Du, X., Tang, Y., Shen, C., Feng, J., Sahakian, B. J., Lin, C.-P., & Li, F.
- Venue
- Translational Psychiatry
- Published
- 2020-01-27
- Volume
- 10
- Issue
- 1
- Pages
- 9-9
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W4239498725
- Cited by
- 134
- References
- 25
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. https://app.cochat.ai/papers/10.1038/s41398-020-0692-2
- The paper
- Zhang, L., Huang, C.-C., Dai, Y., Luo, Q., Ji, Y., Wang, K., Deng, S., Yu, J., Xu, M., Du, X., Tang, Y., Shen, C., Feng, J., Sahakian, B. J., Lin, C.-P., & Li, F. (2020). Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. Translational Psychiatry. https://doi.org/10.1038/s41398-020-0692-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.